Payment overview · 2025
General Payments
$138.39
7 reported records · 6 companies
Healthcare provider profile · identity verified
Ronald Joseph Taylor, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · CYPRESS, TX · NPI 1023091402
Verified facts
What the public records show
CMS Open Payments records show Ronald Joseph Taylor, MD received $138.39 in general payments during 2025 across 7 reported records.
Exact Sciences Corporation accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.21 | 23.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.56 | 17.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.47 | 16.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.53 | 14.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.53 | 14.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.09 | 13.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $138.39 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 487 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 116 |
| Metformin Hcl | Metformin Hcl | 311 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 89 |
| Losartan Potassium | Losartan Potassium | 290 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 69 |
| Gabapentin | Gabapentin | 192 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 53 |
| Furosemide | Furosemide | 178 | 57 |
| Simvastatin | Simvastatin | 178 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 47 |
| Lisinopril | Lisinopril | 147 | 41 |
| Mirtazapine | Mirtazapine | 144 | 46 |
| Alprazolam | Alprazolam | 128 | 35 |
| Potassium Chloride | Potassium Chloride | 121 | 37 |
| Lorazepam | Lorazepam | 120 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 113 | 29 |
| Meloxicam | Meloxicam | 110 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 20 |
| Omeprazole | Omeprazole | 101 | 31 |
| Nifedipine Er | Nifedipine | 96 | 31 |
| Glimepiride | Glimepiride | 92 | 25 |
| Finasteride | Finasteride | 88 | 25 |
| Donepezil Hcl | Donepezil Hcl | 86 | 23 |
| Synthroid | Levothyroxine Sodium | 85 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 56 |
| Famotidine | Famotidine | 78 | 26 |
| Montelukast Sodium | Montelukast Sodium | 76 | 21 |
| Tramadol Hcl | Tramadol Hcl | 73 | 23 |
| Ezetimibe | Ezetimibe | 71 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 20 |
| Metformin Hcl Er | Metformin Hcl | 69 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 18 |
| Trazodone Hcl | Trazodone Hcl | 66 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 19 |
| Sertraline Hcl | Sertraline Hcl | 62 | 17 |
| Cefdinir | Cefdinir | 61 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 22 |
| Eliquis | Apixaban | 58 | 14 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Allopurinol | Allopurinol | 57 | 17 |
| Januvia | Sitagliptin Phosphate | 57 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 16 |
| Azithromycin | Azithromycin | 52 | 46 |
| Methylprednisolone | Methylprednisolone | 48 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 12 |
| Atenolol | Atenolol | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 30 |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 20 |
| Valsartan | Valsartan | 34 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 17 |
| Azelastine Hcl | Azelastine Hcl | 30 | 17 |
| Carvedilol | Carvedilol | 30 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 11 |
| Ramipril | Ramipril | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Febuxostat | Febuxostat | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $138.39 · 7 records | Exact Sciences Corporation | Cologuard Collection Kit, GVOKE HYPOPEN, INSPIRE, JARDIANCE, Ozempic, Rybelsus, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error